Centillion utilizes a patented RNA-By-Design manufacturing platform that combines flow chemistry engineering with extensive data analytics to produce RNA-based vaccines and therapeutics. This technology addresses the need for rapid, scalable, and regulatory-ready drug development, ensuring high yield and purity while minimizing risks in the production process.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods of producing RNA-based vaccines and therapeutics often face challenges in achieving rapid scalability, high yields, and consistent purity while adhering to stringent regulatory requirements. These challenges can slow down drug development timelines and increase production costs.
Solution
Centillion utilizes a patented RNA-By-Design manufacturing platform that combines flow chemistry engineering with extensive data analytics to produce RNA-based vaccines and therapeutics. This platform accelerates the design, production, and provision of RNA-based products with increased yield, scale, and quality by design. The technology addresses the need for rapid, scalable, and regulatory-ready drug development, ensuring high yield and purity while minimizing risks in the production process. Centillion's platform supports innovators through a digitally enabled biologics manufacturing process fueled by novel flow technology. The platform offers seamless, end-to-end scalability from lab through to manufacturing, de-risking propositions and turning ideas into reality.
Target Audience
The primary target audience includes innovators in the healthcare and pharmaceutical industries focused on developing RNA-based vaccines and therapeutics, as well as clinical researchers and partners seeking to accelerate their RNA journey from discovery to manufacture.
Features
- Patented RNA-By-Design manufacturing platform combining flow chemistry and data analytics
- Capability to achieve >90% integrity of pure substance for various RNA types, including self-amplifying RNA
- Platform underpinned by 20,000+ experimental data points for digital process understanding
- 40+ quality attributes and KPIs that underpin the RNA by Design™ process
- Supports mRNA, saRNA, and (x)RNA applications
- Delivers mRNA-based products with >98% purity and >95% encapsulation efficiencies
- dsRNA content consistently below detection levels, meeting GMP manufacturing criteria
- Enables low-dose advantages for self-amplifying RNA through self-replication